Skip to content
Search

Latest Stories

'Pharmacy of the world' India exports first covid vaccines

'Pharmacy of the world' India exports first covid vaccines

India exported its first batch of locally produced coronavirus shots on Wednesday (20), officials said, as the world's biggest vaccine manufacturer scrambled to meet requests from other countries desperate to protect their populations.

The Maldives and Bhutan will be the first recipients of India's coronavirus vaccine, while Brazil and South Africa are also among those on the waiting list.


Foreign minister S. Jaishankar said on Twitter that the "Pharmacy of the World will deliver to overcome the COVID challenge".

The policy is seen in part as a push by India to boost its soft power and take on rival China, which is also supplying vaccines to other countries.

In January, Indian regulators approved two vaccines -- one, Covishield, developed by AstraZeneca and Oxford University and produced by India's Serum Institute, and the other Covaxin, made by local firm Bharat Biotech.

The Indian government said the Maldives will receive a free supply of 100,000 doses of Covishield on Wednesday, while Bhutan will receive 150,000 as a "gift".

Bangladesh, Nepal, Myanmar and Seychelles will follow shortly, New Dehli said.

India plans to offer 20 million doses to its South Asian neighbours, Bloomberg News reported last week, with others in Latin America, Africa and Central Asia next in line.

The Serum Institute, the world's biggest vaccine maker by volume, also plans to supply 200 million doses to Covax, a World Health Organization-backed effort to procure and distribute inoculations to poor countries.

Meanwhile, Covaxin's maker Bharat Biotech last week signed a deal with a Brazilian firm and is ramping up annual production to 700 million doses, a spokesperson told financial outlet the Mint Daily on Wednesday.

India on Saturday began rolling out Covishield and Covaxin jabs to its 1.3 billion people, although the shot for the latter is yet to complete human trials.

As of Wednesday, India had vaccinated almost 675,000 people, according to the government, as it pushes to inoculate 300 million people by July.

But amid some public scepticism and technical problems, many people have not been showing up at appointments to get their first shot.

In the first two days of the rollout in the capital New Delhi, for instance, only 53 percent of people invited came forward for jabs, the city's health minister Satyendar Jain said.

More For You

Prada 2026 sandals

Prada acknowledges Indian influence behind its Spring Summer 2026 men’s footwear

Instagram/prada/iStock

Prada finally acknowledges Kolhapuri chappals inspired 2026 sandals after Indian backlash over Milan show

Quick highlights:

• Prada confirms Indian roots behind 2026 ‘leather sandals’ after controversy
• Indian artisans and officials accused the brand of cultural appropriation
• The footwear resembles traditional Kolhapuri chappals with GI status
• Prada says designs are still in development and open to dialogue with India

Keep ReadingShow less
Anna Wintour

Wintour’s style of leadership earned her the nickname “Nuclear Wintour”

Getty Images

Anna Wintour steps down as editor of US Vogue after 37 years

Key points

  • Anna Wintour steps down as editor of US Vogue after 37 years
  • She will remain Vogue’s global editorial director and hold senior roles at Condé Nast
  • Wintour transformed US Vogue into a global fashion authority
  • The 75-year-old has received numerous honours, including the Presidential Medal of Freedom

End of an era at US Vogue

Anna Wintour has stepped down as the editor of US Vogue, bringing to a close a 37-year tenure that redefined the publication and saw her become one of the most influential figures in global fashion.

The announcement was made on Thursday (26 June) during a staff meeting in New York. Wintour, 75, will no longer oversee the day-to-day editorial operations of Vogue’s US edition. However, she will continue to serve as Vogue’s global editorial director and Condé Nast’s chief content officer, maintaining senior leadership roles across the company.

Keep ReadingShow less
Nadiya Hussain

She also reassured her followers that “exciting” new projects are on the way

Getty Images

“I won’t always be grateful” says Nadiya Hussain after BBC axes her cookery show

Key points

  • Nadiya Hussain confirms BBC will not renew her cookery series
  • Bake Off winner challenges expectations to remain “grateful”
  • She says hard work and talent, not luck, brought her success
  • Celebrities, including Annie Lennox and Fearne Cotton, show support

BBC ends decade-long collaboration with Bake Off star

Nadiya Hussain has spoken out after the BBC decided not to commission another cookery programme with her. The popular TV chef, who won The Great British Bake Off in 2015, shared her views on social media, stating that she “won’t always be grateful” and should not be expected to remain silent about career setbacks.

The decision ends a nearly 10-year working relationship between the broadcaster and Hussain, who has hosted several well-received cookery shows under the BBC banner. In her latest Instagram video, she addressed the public’s reaction and emphasised her right to expect more from her career.

Keep ReadingShow less
weight loss injections UK

The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow

iStock

Hundreds report pancreas issues linked to weight loss injections as UK launches safety study

Key points

  • Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
  • Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
  • Health officials are investigating possible genetic causes behind the side-effects
  • Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
  • Adverse drug reactions cost the NHS an estimated £2.2bn annually

Health watchdog investigates spike in serious side-effects from GLP-1 drugs

UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.

The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.

Keep ReadingShow less
M&S launches strawberries

M&S’s latest offering taps into both tradition and innovation

The Wire

M&S launches strawberries and cream sandwich ahead of Wimbledon

Summary

  • M&S unveils limited edition strawberries and cream sandwich for £2.80
  • Inspired by Japanese 'sweet sandos', it features Red Diamond strawberries and whipped cream cheese
  • Available in stores now, found in the savoury sandwich aisle
  • Launch coincides with Wimbledon and British strawberry season
  • Wimbledon increases strawberries and cream price for first time in 15 years

New summer sandwich from M&S

Marks & Spencer has launched a limited edition M&S strawberry sandwich, combining classic British summer flavours with a Japanese twist. Priced at £2.80, the strawberries and cream sandwich is available in M&S stores now.

The dessert-style sandwich features M&S’s exclusive Red Diamond strawberries, whipped cream cheese, and sweetened bread. Despite its sweet contents, the product is found in the savoury sandwich section of M&S Food halls.

Keep ReadingShow less